Physician profile
Brian Daniel Hochman
NPI 1811371560
$9,770.07
in general payments reported to CMS, 2019-2025
23 companies · $863 in 2025
The $863 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,261 · 2020: $1,533 · 2021: $1,622 · 2022: $656 · 2023: $468 · 2024: $2,367 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609 · Travel and Lodging: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.68 |
| Travel and Lodging | $1,089.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $5,607.63 | 2019-2025 | Prostep, Augment Injectable, Actishield |
| Medinc of Texas | $2,244.00 | 2019-2020 | |
| Wright Medical Technology, INC. | $533.25 | 2019-2020 | |
| Treace Medical Concepts, INC. | $389.72 | 2023-2025 | |
| Smith+Nephew, INC. | $233.05 | 2019-2024 | Grafix Pl |
| Osiris Therapeutics INC. | $119.05 | 2019 | |
| Paratek Pharmaceuticals, INC. | $91.73 | 2020-2022 | |
| Scilex Pharmaceuticals INC. | $64.43 | 2019 | |
| Crossroads Extremity Systems, LLC | $58.33 | 2019 | |
| Arthrex, INC. | $57.98 | 2022 | |
| Bioventus LLC | $51.17 | 2020-2021 | |
| Kerecis Limited | $46.83 | 2019-2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Kaleo, INC. | $40.27 | 2019 | |
| Triad Life Sciences INC. | $38.77 | 2022 | |
| Grt US Holding, INC. | $37.31 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orthofix Medical, INC. | $29.25 | 2019-2020 | |
| Paragon 28, INC. | $26.49 | 2020 | |
| Depuy Synthes Sales INC. | $24.88 | 2021 | |
| Abbott Laboratories | $16.81 | 2025 | Proclaim |
| Acell, INC. | $16.59 | 2019 | |
| Ibsa Pharma INC. | $14.85 | 2021 | |
| Medtronic, INC. | $14.49 | 2025 | Vanta Adaptivestim |
| Horizon Therapeutics Plc | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hochman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.